Pfizer partnered with the Global Alliance for Rabies Control’s Shelter Program to offer the free vaccine doses to more than 130 shelters and clinics nationwide, allowing 50,000 pets to be protected against this deadly disease, as well as reducing the risk of human exposure in communities across the country.

Pfizer Animal Health, a business unit of Pfizer Inc., is a world leader in the discovery, development and manufacture of innovative animal health vaccines, medicines, diagnostic products and genetic tests. Pfizer Animal Health invests more in research and development than any other animal health company.

Zoetis Inc. The company was a subsidiary of Pfizer, the world’s largest drug maker, but with Pfizer’s spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets the products in approximately 45 countries, and sells the products in more than 100 countries.

May 16, 2013
On May 16, 2013, Zoetis, which only three months earlier had been spun off from Pfizer as a completely independent company, got some very welcome news — an FDA approval for APOQUEL (oclacitinib tablet), which helps control severe itching associated with allergic dermatitis in dogs 12 months of age or older.

Zoetis is on the Cruelty Free Investing animal use list due to its use of animal testing in development and testing of its products, as well as its support for the pet and livestock industries.

(NYSE: ZTS), through an exchange offer. Zoetis, formerly Pfizer’s animal health business, completed its initial public offering (IPO) in February 2013. In the exchange offer, Pfizer shareholders can exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis common stock owned by Pfizer.

Zoetis is ethically and legally obliged to rigorously evaluate new medicines and therapies.